R

Relmada Therapeutics
D

RLMD

3.42000
USD
0.08
(2.40%)
مغلق
حجم التداول
1,626
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
103,195,771
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.27000
    (-4.24%)
    6.10000 USD
    B
    BCRX
    -0.19000
    (-2.61%)
    7.10000 USD
    I
    INO
    -0.670
    (-6.28%)
    10.000 USD
    MRNA
    -25.020
    (-20.99%)
    94.160 USD
    N
    NVAX
    -0.250
    (-1.95%)
    12.560 USD
    T
    TNXP
    0.00960
    (1.92%)
    0.51050 USD
    V
    VXRT
    -0.01170
    (-1.74%)
    0.65890 USD
    المزيد
الأخبار
المقالات

العنوان: Relmada Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications.